ONCOLOGY

Conclusion

Glycon’s Melphalan glycoconjugate derivative, GMX-175, is far superior to the parent compound, Melphalan, with respect to its anticancer effects.

 

In culture and human micro assay studies, this compound has shown significant effects that make it an excellent chemotherapeutic candidate against multiple myeloma, breast cancer, histiocytic lymphoma and neuroblastoma.

 

Glycoconjugation of Melphalan increases its anticancer effect on breast cancer, multiple myeloma and neuroblastoma cells. 

 

Methylation of Melphalan, in addition to glycoconjugation significantly increases the ability to inhibit cancer cell proliferation, inhibits cell migration and induces apoptosis.

 

In cell culture and human micro assay studies, this compound has shown significant effects that makes it an excellent chemotherapeutic candidate against multiple myeloma, breast cancer, histiocytic lymphoma and neuroblastoma.

Studies in MDA-MB-231 breast cancer, U937 histiocytic and D54 Neuroblastoma Cells showed that at 10µM, GMX-175, but not Melphalan:

- Inhibits cell proliferation

- Induces programmed cell death

- Inhibits cell migration

GMX-175 was developed using a patented technology designed to increase:

- Aqueous solubility

- Anticancer effects

- Transport across the plasma membrane

Glycon feels that with the superior anticancer activity and increased aqueous solubility of GMX-175 as compared to the parent compound, Melphalan, that further studies are warranted to progress this compound through the FDA process.

  • Facebook Social Icon
  • Twitter Social Icon
GLYCON PHARMA
CONTACT:  MIKE ALLEN
TEL:  (205) 405-4114
EMAIL:
mallen@glyconpharma.com

© 2018 by Glycon Pharma.            Powered by Bright Idea Web Design.